Alex J Mao

Suggest Changes
Learn More
OBJECTIVE To compare visual acuity and central retinal thickness in patients initially treated with bevacizumab (Avastin) and switched to ranibizumab (Lucentis) for neovascular age-related macular(More)
  • 1